P2RX2 and prostate carcinoma: For instance, the addition of ATP-degrading apyrase abolishes ICWs in human mesenchymal stem cells (HMSCs) [79], while both apyrase or purinergic receptor blockers Suramin and PPADS abolish ICWs in FUS-stimulated PC-3 human prostate cancer cells [88].